Johnson & Johnson (NYSE:JNJ) Stock News, Headlines & Updates
Johnson & Johnson Stock News from GuruFocus
- 1
Jul 11, 2024
Johnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26
Business Wire • 7:00am
Jul 08, 2024
Johnson & Johnson: An Exploration into Its Intrinsic Value
GuruFocus Research • 6:00am
Jul 02, 2024
CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study
PRNewswire • 7:00am
Jun 28, 2024
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients
PRNewswire • 11:00am
Jun 27, 2024
Lawyers for Johnson & Johnson's Ovarian Cancer Victims React to SCOTUS Decision in Purdue
Business Wire • 6:00pm
Jun 24, 2024
Beyond Market Price: Uncovering Johnson & Johnson's Intrinsic Value
GuruFocus Research • 6:00am
Jun 21, 2024
Johnson & Johnson Completes Acquisition of Proteologix, Inc.
Business Wire • 7:00am
Jun 20, 2024
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease
PRNewswire • 4:00pm
More than 60 Law Firms Oppose J&J Prepack Bankruptcy Scheme
Business Wire • 1:00pm
TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction
PRNewswire • 8:00am
Jun 17, 2024
Beasley Allen and Levin Papantonio: Leading Law Firms Seek Protection for Future Victims of Johnson & Johnson Talc Products
Business Wire • 5:00pm
Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer
PRNewswire • 8:00am
Jun 15, 2024
Late-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase 2 study
PRNewswire • 3:00am
Jun 14, 2024
TALVEY® (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma
PRNewswire • 8:00am
Jun 12, 2024
Talc Plaintiffs File Motion for Temporary Restraining Order to Limit Johnson & Johnson's Use of Bankruptcy Strategy
Business Wire • 2:00pm
Jun 10, 2024
Invest with Confidence: Intrinsic Value Unveiled of Johnson & Johnson
GuruFocus Research • 6:00am
Jun 04, 2024
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
Business Wire • 4:00pm
May 31, 2024
Johnson & Johnson Completes Acquisition of Shockwave Medical
Business Wire • 8:00am
May 28, 2024
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis
Marketwired • 7:00am
Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis
Business Wire • 7:00am
May 27, 2024
Johnson & Johnson: An Exploration into Its Intrinsic Value
GuruFocus Research • 6:00am
May 22, 2024
Proposed Class Action Filed by Six Law Firms Alleging Series of Fraudulent Transfers by Johnson & Johnson in Talc Litigation
Business Wire • 12:00pm
May 20, 2024
Johnson & Johnson's Dividend Analysis
GuruFocus Research • 5:01am
May 16, 2024
Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment
Business Wire • 7:00am
May 13, 2024
The Art of Valuation: Discovering Johnson & Johnson's Intrinsic Value
GuruFocus Research • 6:00am
May 08, 2024
Johnson & Johnson to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Business Wire • 4:00pm
May 07, 2024
Johnson & Johnson's Spinoff Kenvue (KVUE) Rallies Despite Challenges
GuruFocus Research • 1:14pm
May 02, 2024
Decoding Johnson & Johnson (JNJ): A Strategic SWOT Insight
GuruFocus Research • 11:04pm
May 01, 2024
Unveiling Johnson & Johnson (JNJ)'s Value: Is It Really Priced Right? A Comprehensive Guide
GuruFocus Research • 9:32am
Johnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual “Prepackaged” Reorganization
Business Wire • 6:00am
Apr 29, 2024
The Art of Valuation: Discovering Johnson & Johnson's Intrinsic Value
GuruFocus Research • 6:00am
Apr 22, 2024
Johnson & Johnson to Participate in the Bernstein's 40th Annual Strategic Decisions Conference (SDC)
Business Wire • 4:00pm
- 1
Show
Entries
Headlines
Total 0- 1
No recent news